FDA Panel Narrowly Backs EUA for Merck’s COVID-19 Antiviral

In a 13-10 vote yesterday, an FDA advisory committee recommended that the FDA should grant Emergency Use Authorization (EUA) for molnupiravir, the antiviral pill co-developed by Merck and Ridgeback Biotherapeutics.
Source: Drug Industry Daily